{"status": "ok", "totalResults": 1, "articles": [{"source": {"id": "reuters", "name": "Reuters"}, "author": "Ludwig Burger, John Revill", "title": "Roche buys U.S. rights to Roivant bowel disease drug in $7.1 billion deal - Reuters.com", "description": "Switzerland's Roche <a href=\"https://www.reuters.com/markets/companies/ROG.S\" target=\"_blank\">(ROG.S)</a> has agreed to pay an initial $7.1 billion to Roivant <a href=\"https://www.reuters.com/markets/companies/ROIV.O\" target=\"_blank\">(ROIV.O)</a> and Pfizer <\u2026", "url": "https://www.reuters.com/markets/deals/roche-buys-telavant-holdings-71-billion-2023-10-23/", "urlToImage": "https://www.reuters.com/resizer/kbxe3KiBOJoKw34vXI7NyErt9R8=/1200x628/smart/filters:quality(80)/cloudfront-us-east-2.images.arcpublishing.com/reuters/XUZPCNOO7NMW3JY2FMJMAGTIH4.jpg", "publishedAt": "2023-10-23T09:41:00Z", "content": "ZURICH/FRANKFURT, Oct 23 (Reuters) - Switzerland's Roche (ROG.S) has agreed to pay an initial $7.1 billion to Roivant (ROIV.O) and Pfizer (PFE.N) for rights to a new inflammatory bowel disease drug, \u2026 [+3364 chars]"}]}